Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck CEO not interested in inversion deals

Merck & Co. Inc. (NYSE:MRK) is not interested in pursuing deals "solely or primarily for the specific purpose of tax

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE